$NVAX & $PFE Today’s Research Reports on Stocks to Watch:

New Post Public Reply Private Reply Replies (0) Message Board
jonny_red32
349
$NVAX & $PFE Today’s Research Reports on Stocks to Watch: Novavax and Pfizer

logo.png
200px-Pfizer.svg.png

NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.

RDI Initiates Coverage on:

Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX

Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE

Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.

Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX

Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."

Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE

Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on Tuesday. Shares of Pfizer saw gains after finalizing an agreement with Allogene and announcing that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926 for boys with Duchenne muscular dystrophy.

RDI Initiates Coverage on:

Novavax, Inc.
https://rdinvesting.com/news/?ticker=NVAX

Pfizer Inc.
https://rdinvesting.com/news/?ticker=PFE

Novavax, Inc. shares closed down 12.98% yesterday and continued to see more losses in after-hours trading after Wall Street digested the news that the company had sold 30.3 million shares of common stock to the public at a price of $1.65 per share. Considering that shares closed at $2.08 a share on Wednesday, the $1.65 price was a big discount. According to the company, the proceeds from the offering will be used for general corporate purposes. The offering is anticipated to close on or around April 16, 2018, subject to the satisfaction of customary closing conditions. Trading volume was significant for the stock yesterday at almost 39.5 million shares compared to an average trading volume of just under 10 million shares.

Access RDI's Novavax, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVAX

Pfizer Inc. shares closed up 1.48% yesterday on nearly 22.6 million shares traded. Earlier this week the pharma giant announced that it finalized its agreement with Allogene Therapeutics for its allogeneic CAR-T therapy asset portfolio. It was earlier in the month on April 3rd that Pfizer announced it had entered the agreement to develop cancer therapies. As part of the agreement, Allogene has rights to Pfizer's 16- pre-clinical CAR-T assets from Cellectis and Servier and one clinical asset licensed from Servier, UCART19, an allogeneic CAR-T therapy that is being developed for treatment of CD19-expressing hematological malignancies. David Chang, M.D., Ph.D., the President and CEO of Allogene commented, "The completion of our agreement with Pfizer represents a bold undertaking by leaders in the field to expedite the development of the next wave of cancer immunotherapies." In other news, Pfizer also announced yesterday that it has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). CEO and Founder of Cure Duchenne, Debra Miller, stated, "On behalf of the community of individuals and families living with Duchenne muscular dystrophy, we applaud the important step Pfizer has taken to advance a potentially transformational treatment option for boys stricken with this terrible disease. The momentum we are seeing in the field of gene therapy emphasizes the maturing opportunity to advance the science. Today, there are very limited treatment options for our boys. Through collaboration and ongoing dialogue with companies like Pfizer, we hope to succeed in finding therapies that could dramatically change the outcomes for those with DMD."

Access RDI's Pfizer Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PFE

Our Actionable Research on Novavax, Inc. (NASDAQ: NVAX) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment






Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 406

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 70

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 125

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 97

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 63

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 5

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 67

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding DraftKings Options Activity and Market Trends

Updated Category News Views 194

DraftKings: Analyzing Recent Options Activity In the world of financial trading, few stories capture attention quite like a company's options activity, especially when it comes to a prominent name such as DraftKings (NASDAQ: DKNG). Recently, significant bullish moves by major investors have been noted, illustrating a dynamic shift within the trading environment. Insights...

Continue Reading
Integrating Bitcoin into Modern Investment Strategies

Updated Category News Views 259

Why Bitcoin Is Essential in Today's Investment Landscape For many investors, Bitcoin remains a puzzling investment vehicle. A recent survey revealed that a significant portion of the population lacks confidence in the safety and reliability of cryptocurrencies. However, when industry leaders like BlackRock make statements regarding Bitcoin, it’s wise to take heed....

Continue Reading
Strengthening Global Ties: ICAC's Role in Combating Corruption

Updated Category News Views 240

Strengthening Global Ties: ICAC's Role in Combating Corruption In a significant development, the ICAC Commissioner Mr. Woo Ying-ming represented the International Association of Anti-Corruption Authorities (IAACA) at the G20 Anti-Corruption Working Group meeting, marking the first occasion for the ICAC to participate in such a global dialogue. The meeting brought together...

Continue Reading
FlexTV's New Release: A Drama of Love and Intrigue

Updated Category News Views 447

FlexTV Unveils English Adaptation of a Short Drama Mega Matrix Inc. (NYSE American: MPU) is thrilled to announce the premiere of its much-anticipated short drama Drink Me, Keep Me, Cut Me, now available in English on their streaming platform, FlexTV. This series offers viewers a tantalizing glimpse into the intricate relationship dynamics intertwined with love and...

Continue Reading
Canada Eases Mortgage Switch Process for Borrowers

Updated Category News Views 87

Canada's Mortgage Game-Changer: Easing Lender Switching In a bold move that could shake up the housing market, Canada’s banking regulator has rolled out a directive set to streamline how homeowners switch lenders during mortgage renewals. Finally! This change aims to chop through the red tape that often kept borrowers shackled to less favorable terms. The Short-Term...

Continue Reading